Lanxiang Wu
5PUBLICATIONS
2CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jul 22, 2024
Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis.Yutang Huang, Xiaoqing Wang, Chunjie Wen
|Mar 14, 2024
Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway.Wei-Feng Xia, Xiao-Li Zheng, Wen-Yi Liu
|Jan 18, 2023
Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer.Nan Wang, Qilin Zhao, Yutang Huang
|Jun 18, 2022
Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation.Yutang Huang, Yan Du, Yujie Zheng
|Jun 14, 2022
Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region.Shuai He, Jingjing Shi, HongHao Zhou
Pageof 1
